Landmark study demonstrates economic edge of precision medicine that we can’t afford to ignore.
Experts begin to unlock the commercial potential of precision medicine with the first ever side by side economic analysis Landmark study demonstrates that precision oncology medicines could deliver a superior Return On Investment (ROI) for Pharma R&D vs their one size fits all counterparts but warns that more work needs
27/10/2023